GT BIOPHARMA, INC. (GTBP) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$4.51M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$2.85M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$3.38M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$1.51M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$4.51M | (m) | (m) | (m) | (m) | -$4.26M* | (m) | $1.05M | $3.46M | (m) |
| 2026-03-31 | Reported | (m) | -$2.85M | (m) | (m) | (m) | (m) | -$2.47M | (m) | $413.00K | $2.44M | (m) |
| 2025-09-30 | Reported | (m) | -$3.38M | (m) | (m) | (m) | (m) | -$3.68M* | (m) | $634.00K | $2.75M | (m) |
| 2025-06-30 | Reported | (m) | -$1.51M | (m) | (m) | (m) | (m) | -$3.01M* | (m) | $363.00K | $1.15M | (m) |
| 2025-03-31 | Reported | (m) | -$1.93M | (m) | (m) | (m) | (m) | -$2.20M | (m) | $1.10M | $833.00K | (m) |
| 2024-09-30 | Reported | (m) | -$3.60M | (m) | (m) | (m) | (m) | -$2.74M* | (m) | $1.31M | $2.30M | (m) |
| 2024-06-30 | Reported | (m) | -$3.91M | (m) | (m) | (m) | (m) | -$3.54M* | (m) | $1.78M | $2.12M | (m) |
| 2024-03-31 | Reported | (m) | -$3.09M | (m) | (m) | (m) | (m) | -$4.16M | (m) | $777.00K | $2.31M | (m) |
| 2023-09-30 | Reported | (m) | -$3.12M | (m) | (m) | (m) | (m) | -$1.96M* | (m) | $1.36M | $1.76M | (m) |
| 2023-06-30 | Reported | (m) | -$3.62M | (m) | (m) | (m) | (m) | -$1.94M* | (m) | $2.10M | $1.53M | (m) |
| 2023-03-31 | Reported | (m) | -$3.67M | (m) | (m) | (m) | (m) | -$2.91M | (m) | $1.65M | $2.02M | (m) |
| 2022-09-30 | Reported | (m) | -$7.02M | (m) | (m) | (m) | (m) | -$2.92M* | (m) | $2.74M | $4.28M | (m) |
| 2022-06-30 | Reported | (m) | -$3.01M | (m) | (m) | (m) | (m) | -$2.79M* | (m) | $1.14M | $1.88M | (m) |
| 2022-03-31 | Reported | (m) | -$5.44M | (m) | (m) | (m) | (m) | -$5.21M | (m) | $2.09M | $3.35M | (m) |
| 2021-09-30 | Reported | (m) | -$5.95M | (m) | (m) | (m) | (m) | -$3.93M* | (m) | $1.01M | $4.95M | (m) |
| 2021-06-30 | Reported | (m) | -$4.38M | (m) | (m) | (m) | (m) | -$4.29M* | (m) | $639.00K | $3.74M | (m) |
| 2021-03-31 | Reported | (m) | -$29.00M | (m) | (m) | (m) | (m) | -$3.68M | (m) | $1.64M | $27.36M | (m) |
| 2020-09-30 | Reported | (m) | -$1.95M | (m) | (m) | (m) | (m) | -$1.70M* | (m) | $84.00K | $2.03M | $0.00 |
| 2020-06-30 | Reported | (m) | -$1.56M | (m) | (m) | (m) | (m) | -$3.41M* | (m) | $12.00K | $1.55M | $0.00 |
| 2020-03-31 | Reported | (m) | $1.07M | (m) | (m) | (m) | (m) | -$223.00K | (m) | $324.00K | $746.00K | $0.00 |
| 2019-09-30 | Reported | (m) | -$8.86M | (m) | (m) | (m) | $0.00* | -$1.13M* | (m) | $671.00K | $3.58M | $0.00 |
| 2019-06-30 | Reported | (m) | -$2.28M | (m) | (m) | (m) | $0.00* | -$1.09M* | (m) | $154.00K | $2.13M | $0.00 |
| 2019-03-31 | Reported | (m) | -$4.06M | (m) | (m) | (m) | $0.00 | -$961.00K | (m) | $834.00K | $3.22M | $0.00 |
| 2018-09-30 | Reported | (m) | -$234.66M | (m) | (m) | (m) | $2.00K* | -$3.43M* | (m) | $1.11M | $5.04M | $0.00 |
| 2018-06-30 | Reported | (m) | -$5.16M | (m) | (m) | (m) | $0.00* | -$1.77M* | $0.00 | $3.25M | $1.91M | $0.00 |
| 2018-03-31 | Reported | (m) | -$7.16M | (m) | (m) | (m) | $2.00K | -$4.23M | $0.00 | $3.47M | $3.69M | $0.00 |
| 2017-09-30 | Reported | (m) | -$126.86M | (m) | (m) | (m) | $0.00* | -$2.24M* | $0.00 | $526.00K | $126.33M | $0.00 |
| 2017-06-30 | Reported | (m) | -$1.28M | (m) | (m) | (m) | $0.00* | -$391.00K* | $0.00 | $241.00K | $1.04M | $0.00 |
| 2017-03-31 | Reported | (m) | -$1.54M | (m) | (m) | (m) | $0.00 | -$650.00K | $0.00 | $144.00K | $1.39M | $0.00 |
| 2016-09-30 | Reported | (m) | -$2.53M | (m) | (m) | (m) | (m) | -$563.00K* | $0.00 | $250.00K | $2.28M | $0.00 |
| 2016-06-30 | Reported | (m) | -$2.12M | (m) | (m) | (m) | (m) | -$1.06M* | $0.00 | $250.00K | $1.87M | $0.00 |
| 2016-03-31 | Reported | (m) | -$3.90M | (m) | (m) | (m) | (m) | -$167.00K | $0.00 | $225.00K | $3.68M | $0.00 |
| 2015-09-30 | Reported | (m) | -$2.78M | (m) | (m) | (m) | (m) | -$633.00K* | $0.00 | $225.00K | $2.55M | $0.00 |
| 2015-06-30 | Reported | (m) | -$1.43M | (m) | (m) | (m) | (m) | -$1.29M* | $0.00 | $0.00 | $1.45M | $0.00 |
| 2015-03-31 | Reported | (m) | -$1.81M | (m) | (m) | (m) | (m) | -$1.79M | $0.00 | $250.00K | $1.57M | $0.00 |
| 2014-09-30 | Reported | (m) | -$549.00K | (m) | (m) | (m) | (m) | -$578.00K* | $5.00K | $0.00 | $547.00K | $0.00 |
| 2014-06-30 | Reported | (m) | -$104.00K | (m) | (m) | (m) | (m) | -$43.00K* | $17.00K | $0.00 | $112.00K | $0.00 |
| 2014-03-31 | Reported | (m) | -$101.00K | (m) | (m) | (m) | (m) | -$90.00K | $0.00 | $0.00 | $101.00K | $0.00 |
| 2013-09-30 | Reported | (m) | -$140.00K | (m) | (m) | (m) | (m) | $45.00K* | $123.00K | $0.00 | $200.00K | $0.00 |
| 2013-06-30 | Reported | (m) | (m) | (m) | (m) | (m) | (m) | $20.00K* | (m) | $0.00 | (m) | $0.00 |
| 2013-03-31 | Reported | (m) | -$347.00K | (m) | (m) | (m) | (m) | -$138.00K | $69.00K | $0.00 | $366.00K | $0.00 |
| 2012-09-30 | Reported | (m) | -$1.35M | (m) | (m) | (m) | (m) | -$278.00K* | $32.00K | $0.00 | $1.44M | $0.00 |
| 2012-06-30 | Reported | (m) | -$1.03M | (m) | (m) | (m) | (m) | -$303.00K* | $0.00 | $0.00 | $1.03M | $0.00 |
| 2012-03-31 | Reported | (m) | -$396.00K | (m) | (m) | (m) | (m) | -$192.00K | $1.00K | $0.00 | $397.00K | $0.00 |
| 2011-09-30 | Reported | (m) | -$541.00K | (m) | (m) | (m) | (m) | -$99.00K* | $8.00K | $0.00 | $535.00K | $0.00 |
| 2011-06-30 | Reported | (m) | -$481.00K | (m) | (m) | (m) | (m) | -$393.00K* | $15.00K | $28.00K | $439.00K | $0.00 |
| 2011-03-31 | Reported | (m) | -$1.86M | (m) | (m) | (m) | (m) | -$147.00K | $25.00K | $21.00K | $1.83M | (m) |
| 2010-09-30 | Reported | (m) | -$654.00K | (m) | (m) | (m) | (m) | -$390.00K* | $0.00 | $66.00K | $588.00K | $0.00 |
| 2010-06-30 | Reported | (m) | -$386.00K | (m) | (m) | (m) | (m) | (m) | $0.00 | $89.00K | $297.00K | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$12.42M | (m) | (m) | (m) | (m) | -$12.91M | (m) | $3.47M | $8.95M | (m) |
| 2024-12-31 | Reported | (m) | -$14.36M | (m) | (m) | (m) | (m) | -$12.90M | (m) | $5.80M | $8.57M | (m) |
| 2023-12-31 | Reported | (m) | -$13.58M | (m) | (m) | (m) | (m) | -$8.85M | (m) | $6.47M | $7.11M | (m) |
| 2022-12-31 | Reported | (m) | -$21.26M | (m) | (m) | (m) | (m) | -$15.22M | (m) | $8.81M | $12.45M | (m) |
| 2021-12-31 | Reported | (m) | -$57.52M | (m) | (m) | (m) | (m) | -$15.61M | (m) | $9.59M | $47.92M | (m) |
| 2020-12-31 | Reported | (m) | -$6.76M | (m) | (m) | (m) | (m) | -$7.26M | (m) | $485.00K | $6.28M | (m) |
| 2019-12-31 | Reported | (m) | $16.06M | (m) | (m) | (m) | $0.00 | -$3.66M | (m) | $1.67M | $9.79M | $0.00 |
| 2018-12-31 | Reported | (m) | -$250.07M | (m) | (m) | (m) | $36.00K | -$10.68M | (m) | $9.07M | $12.49M | $0.00 |
| 2017-12-31 | Reported | (m) | -$135.57M | (m) | (m) | (m) | $4.00K | -$5.43M | $0.00 | $1.07M | $134.50M | $0.00 |
| 2016-12-31 | Reported | (m) | -$9.37M | (m) | (m) | (m) | $0.00 | -$1.93M | $0.00 | $975.00K | $8.40M | $0.00 |
| 2015-12-31 | Reported | (m) | -$8.93M | (m) | (m) | (m) | $1.00K | -$4.66M | $0.00 | $1.00M | $7.95M | $0.00 |
| 2014-12-31 | Reported | (m) | -$2.40M | (m) | (m) | (m) | $6.00K | -$1.75M | $57.00K | $0.00 | $2.40M | $0.00 |
| 2013-12-31 | Reported | (m) | -$793.00K | (m) | (m) | (m) | $0.00 | -$442.00K | $226.00K | $0.00 | $935.00K | $0.00 |
| 2012-12-31 | Reported | (m) | -$3.51M | (m) | (m) | (m) | $2.00K | -$987.00K | $94.00K | $0.00 | $3.36M | $0.00 |
| 2011-12-31 | Reported | (m) | -$3.93M | (m) | (m) | (m) | $0.00 | -$963.00K | $48.00K | $17.00K | $3.47M | $0.00 |
| 2010-12-31 | Reported | (m) | -$2.50M | (m) | (m) | (m) | (m) | -$1.53M | $65.00K | $179.00K | $2.26M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |